Kurzfassung

A randomized, double-blind, placebo- and active controlled multicenter trial to demonstrate efficay of subcutaneous secukinumab compared to placebo and etanercept ( in a single-blinded arm)after twelve weeks of treatment, and to assess the safety, tolerability, and long-term efficacy in subjects from 6 to less than 18 years of age with severe chronic psoriasis